P199 Clinical outcomes up to week 48 of ongoing filgotinib rheumatoid arthritis long-term extension trial of biologic disease modifying anti-rheumatic drugs inadequate responders initially on filgotinib or placebo in a Phase 3 trial

Abstract Background/Aims The preferential Janus kinase-1 inhibitor filgotinib (FIL) is approved to treat RA in Europe. We assessed FIL efficacy/safety in patients (pts) with inadequate response (IR) to biologic DMARDs (bDMARDs) in a long-term extension trial (LTE; NCT03025308) enrolled from a Phase 3 parent study (PS; NCT02873936). Methods bDMARD-IR pts received FIL 200mg (FIL200), 100mg (FIL100), or placebo (PBO) and stable conventional synthetic (cs)DMARDs up to 24 weeks (W). At W14 of the PS, pts with IR to FIL or PBO (